Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-2

NCT02607618 is registered in ClinicalTrials.gov with Motif Bio as lead sponsor.

NCT NCT02607618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02607618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-2
Lead sponsor
Motif Bio
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2015
Completion date
August 8, 2017
Enrollment
613 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

skin structures and soft tissue infections